MedTrace Logo

Managed Access Program of Venglustat in Pediatric and Adult Patients With Type 3 Gaucher Disease (GD3).

NCT07675031 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-06-30

No results posted yet for this study

Summary

The objective of this program is to provide early access to venglustat for certain patients with Gaucher disease type 3 in response to unsolicited requests from healthcare providers. No approved therapies for the CNS manifestations of the disease are currently available. The program will provide access to venglustat prior to registration and the availability of commercial product (including reimbursement where applicable) in the country of the patient.

Conditions

  • Type 3 Gaucher Disease

Interventions

DRUG

GZ402671

Patients will receive venglustat tablets orally.

Sponsors & Collaborators

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07675031 on ClinicalTrials.gov